MedTrace Logo

Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung

NCT01225965 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-01-29

No results posted yet for this study

Summary

To investigate the physical inflammation inhibition effects of EIL (Ectoin-Hydro-Complex) in subjects of the established SALIA-cohort and the preventive effects on lung function decline.

Conditions

  • COPD
  • Particulate Matter Induced Inflammation of the Lung

Interventions

DEVICE

Ectoin Inhalation Solution

Once daily inhalation of Ectoin Inhalation Solution

DEVICE

Placebo

Once daily inhalation of Placebo Inhalation Solution

Sponsors & Collaborators

  • Bitop AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
75 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-02-28
Completion
2011-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01225965 on ClinicalTrials.gov